Workflow
Globenewswire
icon
Search documents
Alignment Healthcare Names Matt Eyles Executive Vice President of Government & Business Strategy
Globenewswire· 2025-09-08 12:00
Seasoned industry leader to strengthen company’s strategic engagement and policy voice in Medicare AdvantageORANGE, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today announced that Matt Eyles will join as executive vice president of government and business strategy, effective Sept. 29. In this newly created position, Eyles will report directly to Alignment founder and CEO John Kao, elevating Alignment’s engagement and leadership in health care policy at federal and s ...
Aqua Metals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Globenewswire· 2025-09-08 12:00
Company remains in good standing on Nasdaq Capital Market; strengthens platform to execute commercialization and growth strategyRENO, Nev., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a leader in sustainable lithium battery recycling, today announced that it has received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market and that the m ...
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
Globenewswire· 2025-09-08 12:00
BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead investigational therapy, BA-101, for the treatment of Glioblastoma (GBM). GBM is an aggressive primary brain tumor with limited treatment options and poor prognosis under current standa ...
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
Globenewswire· 2025-09-08 12:00
FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany continues preparations for enabling initiation of the Phase 3 study with the goal of advancing the study with a strategic partner early next yearCompany maintains previous guidance for completion of a strategic partnership with one of our advanced clinical assets this year SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global ...
Rectitude Holdings Announces $32.6 Million Standby Equity Purchase Agreement to Launch a Bitcoin Treasury Strategy
Globenewswire· 2025-09-08 12:00
SINGAPORE, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rectitude Holdings Ltd. (Nasdaq: RECT; the “Company” or “Rectitude”), a Singapore-based provider of safety equipment and related industrial products, today announced that it is initiating a Bitcoin treasury strategy via entering into a Standby Equity Purchase Agreement (the “SEPA”) with Constantinople Limited, a British Virgin Islands Company led by Tian Jia, an experienced Bitcoin investor, as Lead Investor, and Chen Zhiqiang, former co-founder and CTO of Tron, ...
Mohist AI Limited Launches TranGPT, an AI Translation and TTS SaaS Platform Empowering Cross-Border Professionals
Globenewswire· 2025-09-08 11:56
The Hong Kong–based company introduces a multilingual AI-powered communication tool designed for e-commerce sellers, financial professionals, and global enterprises.Hong Kong, China, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Mohist AI Limited, a Hong Kong–registered technology company, today announced the official launch of TranGPT, a multilingual AI-powered translation and text-to-speech (TTS) Software-as-a-Service (SaaS) platform. Built for cross-border e-commerce, international finance, and global business, Tra ...
SINTX Technologies Announces Successful Exercise of Warrants for $3.8 Million Gross Proceeds
Globenewswire· 2025-09-08 11:54
SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,099,431 shares of common stock of the Company originally issued in February 2025, having an exercise price of $3.32 per share. The shares of ...
Alterity Therapeutics Raises A$20.0 million in Strategic Placement
Globenewswire· 2025-09-08 11:35
MELBOURNE, Australia and SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received binding commitments for a capital raising of A$20.0 million (the “Placement”) of fully paid ordinary shares (“New Shares”) to International and Australian professional investors. "We are thankful for the continued inte ...
Sparton Resources Inc. Pense Critical Metals Project Exploration Permits Received
Globenewswire· 2025-09-08 11:30
New Massive Sulphide Mineralization FoundTORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sparton Resources Inc. (TSXV-SRI) ("Sparton" or the "Company”) announced today that field operations are underway at the Pense Critical Metals Project near Englehart in Northern Ontario and Quebec. The Pense mineralization exhibits many similarities to the world-class Outokumpu deposits in Finland. Results of the initial drill program and Ontario Junior Exploration Program (“OJEP”) funding assistance at Pense on the Ontario ...
PharmaCorp to Acquire a Pharmacy in Ontario for $5,300,000, New Non-Binding Letter of Intent to Acquire Two Pharmacies in Eastern Canada, Updates on Previously Announced Non-Binding Letters of Intent and Filing of Q2 Investor Presentation
Globenewswire· 2025-09-08 11:30
SASKATOON, Saskatchewan, Sept. 08, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce the signing of a definitive share purchase agreement to acquire a 100% interest in a PharmaChoice Canada bannered pharmacy business located in Ontario (the “Acquisition”). This transaction marks PharmaCorp’s first acquisition under its charter company structure, which was established through the purchase completed on April 30, 2025. In addition, PharmaCorp ha ...